NuScale Power’s (NASDAQ: SMR) most alarming data point this cycle is not a price target cut but a revenue figure: Q2 2026 brought in just $0.1 million, down from $8.1 million in the same period a year earlier.
That collapse in engineering revenue has sharpened disagreement among Wall Street analysts, who now sit on opposite ends of a wide valuation spectrum as the stock fell 10.00%.
Analysts at Barclays, UBS, Citi, and Goldman Sachs have adopted Underweight or Sell stances, clustering their price targets in a $4 to $6 range that implies further downside from current levels.
Their concern centers on the absence of binding, financed module orders and the 2023 cancellation of the Carbon Free Power project, which Wedbush and Barclays both cite as evidence of persistent execution risk.
On the other side, B. Riley and Canaccord maintain Buy ratings, arguing that the broad reset across nuclear and alternative energy stocks has created an attractive entry point for patient investors.
Cantor Fitzgerald adds a more specific bull case, pointing to fabrication progress under the Doosan Enerbility contract, active power purchase agreement discussions with the Tennessee Valley Authority through ENTRA1, and a reported liquidity cushion of roughly $1.9 billion.
The divergence in analyst views has fed through to the consensus fair value estimate, which analysts have now marked down from $10.38 to $8.59 per share.
Underlying model assumptions shifted in several directions simultaneously, with the revenue growth forecast actually rising sharply from 237.34% to 414.01%, even as the future price-to-earnings multiple compressed from 148.54x to 132.47x.
The discount rate edged higher from 9.23% to 9.38%, while the expected profit margin assumption moved marginally in NuScale’s favor, from 11.15% to 11.52%.
Supporting the longer-term bull thesis are two NRC standard design approvals, a supplier manufacturing program spanning more than 60 partners, and a six-module RoPower project planned for Romania.
Class action headlines and the lack of commercial contract momentum remain the key variables that bearish analysts argue the $1.9 billion cash balance alone cannot resolve.
The central question for investors is whether NuScale can convert its regulatory credentials and fabrication progress into signed, financed agreements before its liquidity advantage becomes a liability narrative.